Pfizer’s earlier Phase 1 trial on 144 children.will begin being tested across a group of 4,500 kids aged under 12 in the US, Finland and Spain using a low dosage, the company said Tuesday. It follows Pfizer testing a higher dosage of the shot in an
The lower dosage will be 3 micrograms for kids aged under 5, and 10 micrograms for kids aged between 5 and 11, Pfizer said.
“Today marks an important next step in our efforts to understand the safety and immune response of our COVID-19 vaccine as we initiate the Phase 2/3 trial in children 5-11 years of age,” Dr. Bill Gruber, SVP of Clinical Research and Development at Pfizer, said in a statement. “In the coming weeks, we plan to initiate Phase 2/3 in children 2-4 years of age and in children as young as six months.”
According to Reuters, Pfizer will have data on the older batch of children by September to seek emergency use authorization, and data on kids aged 2 to 5 after that. Data on the vaccine in infants will arrive by November, Reuters said.
Pfizer is also currently seeking— it’s currently being administered under an emergency use authorization.
Pfizer’s COVID-19 vaccine received final approval by the US Centers for Disease Control and Prevention for use inin May.
As of Tuesday, the US has fully vaccinated more than 140 million people, or nearly 42% of the population, according to data from Johns Hopkins University. President Joe Biden has set a goal of 70% of adults in the US to have at least their , pointing to incentives like , .
The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.